We are live on ! Find out more
CTXR icon

Citius Pharmaceuticals
CTXR

39 hedge funds and large institutions have $19.3M invested in Citius Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 12 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,100% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 1

945% more capital invested

Capital invested by funds: $1.85M → $19.3M (+$17.5M)

425% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 4

77% more funds holding

Funds holding: 22 → 39 (+17)

0.2% more ownership

Funds ownership: 0.13% → 0.33% (+0.2%)

Holders
39
Holders Change
+17
Holders Change %
+77.27%
% of All Funds
0.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
12
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$6.87M
2
BlackRock
BlackRock
New York
+$3.07M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.54M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.13M
5
SM
Sabby Management
Florida
+$500K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$151K
2
FIG
Freed Investment Group
Massachusetts
-$22.1K
3
TSS
Two Sigma Securities
New York
-$21K
4
WAM
Warberg Asset Management
Illinois
-$20K
5
CHA
Cooper/Haims Advisors
New York
-$10K
Name Holding Trade Value Shares
Change 		Change in
Stake
WSTAM
26
Wilbanks Smith & Thomas Asset Management
Virginia
$36K – – –
FIG
27
Freed Investment Group
Massachusetts
$26K -$22.1K -556 -49%
CAN
28
Cetera Advisor Networks
California
$25K +$22.3K +560 New
US Bancorp
29
US Bancorp
Minnesota
$20K +$1.59K +40 +10%
T. Rowe Price Associates
30
T. Rowe Price Associates
Maryland
$19K – – –
BJL
31
Brighton Jones LLC
Washington
$18K +$15.9K +400 New
RWP
32
RWA Wealth Partners
Massachusetts
$18K +$15.9K +400 New
Barclays
33
Barclays
United Kingdom
$17K +$14.9K +374 New
Wells Fargo
34
Wells Fargo
California
$5K +$717 +18 +20%
CAPTRUST Financial Advisors
35
CAPTRUST Financial Advisors
North Carolina
$4K +$3.98K +100 New
CP
36
Corbenic Partners
Pennsylvania
$3K – – –
WAS
37
Winch Advisory Services
Wisconsin
$2K +$1.59K +40 New
GWM
38
Geneos Wealth Management
Colorado
$1K +$796 +20 New
VF
39
Virtu Financial
New York
– -$151K -5,907 Closed
TSS
40
Two Sigma Securities
New York
– -$21K -822 Closed
WAM
41
Warberg Asset Management
Illinois
– -$20K -800 Closed
CHA
42
Cooper/Haims Advisors
New York
– -$10K -400 Closed
WAS
43
Wealth Advisory Solutions
Indiana
– +$1.59K +40 +0.9%
1
2

CTXR Hedge Fund Activity: Q1 2021 in Review

39 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q1 2021, worth a combined $19.3M — up 945% from $1.85M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new CTXR positions and 4 closed out — a net gain of 17 holders — while 12 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, adding an estimated $6.87M. The largest seller was Virtu Financial, exiting entirely with an estimated $151K sold.

  • 39 institutional investors held Citius Pharmaceuticals (CTXR) as of Q1 2021, up from 22 in Q4 2020.
  • Funds reported $19.3M of Citius Pharmaceuticals stock for Q1 2021, up 945% quarter-over-quarter.
  • 21 funds opened new Citius Pharmaceuticals positions in Q1 2021 and 4 closed out, a net change of +17 holders.
  • The largest Citius Pharmaceuticals buyer in Q1 2021 was Vanguard Group, an estimated $6.87M added.
  • The largest Citius Pharmaceuticals seller in Q1 2021 was Virtu Financial, an estimated $151K sold.

Based on aggregated 13F filings for Q1 2021.